Although several cost-effectiveness analyses of the prophylactic use of G-CSF among lymphoma patients who are undergoing CHOP-based chemotherapy have been published in the past few years [6–9], the results have been varied (Table 1). The gene discussed is CSF3; the disease is lymphoma.